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Introduction
Since the discovery of insulin in the 1920s there 
have been many advances in the treatment of dia-
betes. In particular, improved formulations of 
insulin as well as better insulin delivery systems 
have meant that our ability to manage diabetes is 
considerably enhanced. Yet, despite these inno-
vations, hypoglycaemia resulting from excess 
exogenous insulin remains an all too common 
metabolic adverse effect of insulin therapy. 
Hypoglycaemia is greatly feared and is a barrier to 
achieving near-normoglycaemia.1 Hypoglycaemia 
in people with type 1 and longer duration type 2 
diabetes results from a variety of factors, some 
dependent on the individual with diabetes and 
some a result of the pathophysiological conse-
quences of beta-cell destruction. Errors in self-
management can and do lead to hypoglycaemia 
and are perhaps to be expected given the burden 
of managing a chronic disease with its significant 
demands on the individual. However, underlying 
abnormalities in the normal counter-regulatory 
response that are present in nearly all people with 
type 1 and longer-duration insulin-treated type 2 
diabetes also markedly increase the propensity to 
hypoglycaemia.2
In people with type 1 diabetes (T1D), autoim-
mune destruction of the pancreatic beta cells 
leads to absolute insulin deficiency and the need 
for insulin replacement therapy. Insulin deliv-
ered exogenously is not under normal physiologi-
cal feedback and therefore may lead to the 
development of hypoglycaemia even in the pres-
ence of intact counter-regulatory responses. The 
risk of hypoglycaemia is also increased markedly 
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with increasing disease duration and strict gly-
caemic control.2 This is because, over time, the 
hormonal counter-regulatory response to hypo-
glycaemia in T1D is suppressed. This relates to 
two additional physiological defects. Firstly, the 
glucagon response to hypoglycaemia is lost in the 
first few years following diagnosis. Secondly, the 
catecholamine response to hypoglycaemia is also 
impaired, both as an effect of disease duration 
and exposure to recurrent hypoglycaemia.2 These 
pathophysiological changes lead to a diminished 
counter-regulatory response with reduced endog-
enous glucose production during hypoglycaemia, 
which is also associated with a reduced sympto-
matic response. In combination, they markedly 
increase the propensity of progressive and severe 
hypoglycaemia in T1D.
As a result of these changes, the average person 
with T1D experiences approximately two epi-
sodes of hypoglycaemia a week,3,4 a figure that 
has not changed significantly over the past 
20 years despite improvements in insulin prepara-
tions. The incidence of asymptomatic hypogly-
caemia is even greater, with the average person 
with T1D experiencing, on average, four episodes 
per week.5 It is now well established that exposure 
to recurrent hypoglycaemia leads to the develop-
ment of impaired awareness of hypoglycaemia 
(IAH), defined as ‘a diminished ability to perceive 
the onset of acute hypoglycaemia’.6 This compli-
cation affects approximately a quarter of all peo-
ple with T1D and, notably, the incidence of IAH 
has not changed in the last 2–3 decades despite 
the introduction of insulin analogues and 
improved insulin delivery systems.7 The risk of 
severe hypoglycaemia, where there is a need for 
external assistance for recovery, is increased six-
fold in people with IAH.8
In this review article, we will address the clinical 
strategies that may help in the management of the 
patient with IAH with or without problematic 
hypoglycaemia, with a focus initially on how to 
identify such patients and then on the variety of 
approaches that may be taken to minimise hypogly-
caemia risk. No single approach can be advocated 
for all patients, and it is the role of the healthcare 
professional to identify the clinical strategy that best 
enables their patient to achieve this goal.
Identifying those at risk
Before putting strategies in place to assist with 
improving awareness of hypoglycaemia, it is key 
that those at risk of severe hypoglycaemia and/or 
who have IAH are identified in the clinic. Severe 
hypoglycaemia risk is highest in those who have 
already experienced an episode of severe hypogly-
caemia in the past or who have IAH.8,9 It is also 
increased in young children and the elderly, those 
with comorbidities such as renal or hepatic dis-
ease, gastroparesis or coeliac disease, or with 
other endocrine disorders that increase the risk of 
hypoglycaemia (e.g. Addison’s Disease), as well 
as with certain behaviours (alcohol excess, 
unplanned exercise, multiple self-correction insu-
lin dosing) and with poor insulin management. 
Longer disease duration is also associated with 
lower intensity autonomic symptoms and a higher 
prevalence of IAH, suggesting that subjective 
symptoms change over time.10 Interestingly, 
HbA1c is not in itself a good predictor of severe 
hypoglycaemia in people with T1D.11
A careful clinical history, when combined with a 
validated objective questionnaires of hypogly-
caemia awareness such as those developed by 
Gold,8 Clarke,12 Pedersen-Bjergaard,13 and the 
HypoCOMPaSS study group,14 are useful in 
establishing a diagnosis of IAH. However, these 
questionnaires do not fully account for the impact 
of asymptomatic hypoglycaemia. Recently, using 
blinded continuous glucose monitoring (CGM) 
in 153 unselected patients with T1D, it was 
reported that those experiencing more frequent 
episodes of asymptomatic hypoglycaemia had 
reduced awareness of hypoglycaemia, longer 
duration of diabetes and tighter glycaemic control 
with lower HbA1c.15 Therefore, while objective 
questionnaires are useful, they will not identify 
those with recurrent asymptomatic hypoglycae-
mia or those who test infrequently. In this con-
text, continuous or Flash glucose monitoring 
(GM) may help identify those with recurrent 
asymptomatic hypoglycaemia.
Education
For individuals with IAH or who have experi-
enced severe hypoglycaemia, education, both 
hypoglycaemia-specific as well as around insulin 
and carbohydrate management, remains the cor-
nerstone of any therapeutic intervention. Low 
numeracy skills have been shown to be adversely 
associated with diabetes control,16 and while 
self-monitoring of blood glucose is associated 
with improved glycaemic control it remains 
infrequent.17 There are a number of structured 
education programmes focussing on the clinical 
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management of hypoglycaemia and improving 
hypoglycaemia awareness.
Education focusing on the clinical management 
of hypoglycaemia
The Diabetes Teaching and Treatment pro-
gramme (DTTP), designed in Germany, was one 
of the first educational programmes designed to 
optimise insulin management in T1D. The DTTP 
was a 5-day in-patient course for T1D with a 
structured written curriculum taught by trained 
educators. The programme focussed on separat-
ing basal and meal-time bolus insulin doses, inten-
sive self-monitoring blood glucose (SMBG) and 
carbohydrate counting to allow a flexible diet.18 
Hypoglycaemia was not addressed specifically. 
The DTTP educational intervention was shown 
to result in a sustained improvement in HbA1c 
and a reduction in the incidence of severe hypo-
glycaemia over 12 years of follow up.19,20 However, 
as these were follow-up observational studies there 
was no control group for comparison.
In the United Kingdom (UK), Dose Adjusted for 
Normal Eating (DAFNE) was developed as 
structured education course based on the DTTP. 
In a randomised, controlled trial of the DAFNE 
intervention, participants who had attended the 
DAFNE course showed significant improvements 
in HbA1c after 6 months, but no significant reduc-
tion in the incidence of severe hypoglycaemia.21 A 
subsequent, 1-year follow up of this cohort 
showed a small but significant reduction in the 
percentage of individuals reporting IAH.22 
Consistent with these findings, the Tayside 
Insulin Management (TIM) structured education 
programme resulted in a significant reduction in 
HbA1c (mean 0.4%) after 6 months of participa-
tion and improved awareness of hypoglycaemia in 
25% of participants, as well as reduction in inci-
dence of severe hypoglycaemia.23
Structured educational programmes are now 
advocated for all people with T1D and, at least in 
the short-term, appear to result in improved con-
trol without additional hypoglycaemia risk. It is 
less clear whether, used alone, they can effec-
tively restore hypoglycaemia awareness and 
reduce severe hypoglycaemia without more spe-
cific education on hypoglycaemia avoidance.24,25 
Hypoglycaemia awareness was not always objec-
tively assessed in these studies and numbers of par-
ticipants were too small to draw reliable conclusions 
about frequency of severe hypoglycaemia.
Education and psychological interventions 
focussing on improving awareness of 
hypoglycaemia
To compliment the structured educational pro-
grammes, a number of groups have combined 
hypoglycaemia-specific education with psycho-
logical training and support. The Recovery of 
Hypoglycaemia Awareness in Longstanding T1D 
(HypoCOMPaSS) trial employed a brief educa-
tional intervention focussed on detection of hypo-
glycaemia.26 This 24-week study randomised 
people with T1D and IAH, to insulin pumps 
(CSII) or multiple daily injections (MDI) with or 
without CGM. All groups underwent the educa-
tional intervention. Interestingly, in all groups 
there was a highly significant (50%) reduction in 
time in hypoglycaemia (<3.0 mmol/l), and an 
improvement in hypoglycaemia awareness.27 
Neither CGM nor CSII (or a combination of 
both) showed any advantage over education and 
ongoing support.27 Of note, compliance with 
CGM was suboptimal, participants wore sensors 
for a median of 57% of time in the study.27 It is 
therefore possible that any additional benefit of 
CGM was missed. It is also possible, given how 
brief the initial hypoglycaemia educational pro-
gramme was, that the main benefit from the inter-
ventions came from the weekly contact and review 
of glucose profiles by the research team.
The Blood Glucose Awareness Training 
Programme (BGAT) is an 8-week programme 
that uses weekly skills-based training sessions to 
improve an individual’s ability to focus on inter-
nal cues to detect, anticipate, avoid and treat both 
hyperglycaemia and hypoglycaemia as well as to 
identify external cues that increase hypoglycae-
mia risk.28 BGAT has been shown to improve 
accuracy of hypoglycaemia testing in those with 
IAH and to reduce hypoglycaemia events in those 
with intact awareness,29,30 with benefits sustained 
for up to 5 years.31 Using a similar approach to 
BGAT, but focussing specifically on hypoglycae-
mia and those suffering from recurrent hypogly-
caemia, Hypoglycaemia Anticipation, Awareness 
and Treatment Training (HAATT) is a psychoe-
ducational programme that has been shown to 
reduce rates of both moderate and severe hypo-
glycaemia in people with T1D without compro-
mising glycaemic control.32
HyPOS is another structured education pro-
gramme (weekly 90-min group education ses-
sions over 5 weeks) for people with T1D and 
IAH.33 When compared with standard education, 
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HyPOS was shown to improve hypoglycaemia 
awareness after 6 months and to reduce the fre-
quency of severe hypoglycaemia after 31 months 
in those subjects with T1D and IAH; although 
there was also a 4-fold reduction in severe hypo-
glycaemia following standard education in this 
study.34
Most recently, DAFNE-Hypoglycaemia Awareness 
Restoration Training (DAFNE-HART) has been 
developed as a psychoeducational training pro-
gramme designed for people who, despite com-
pleting the DAFNE course, continue to experience 
IAH with high rates of severe hypoglycaemia.35 
The study recruited people with T1D and IAH 
assessed using the Gold score.8 DAFNE-HART 
uses motivational interviewing and cognitive 
behavioural therapy, and, in a small pilot study, 
has been shown to reduce severe hypoglycaemia 
and improve hypoglycaemia awareness.35 These 
improvements were achieved without a compro-
mise or deterioration in glycaemic control. This 
was a small-scale uncontrolled pilot study, but 
undoubtedly suggests that targeting unhelpful 
thought processes and beliefs may be effective for 
some individuals. A larger scaled, adequately pow-
ered RCT is underway to test this hypothesis.
Insulin preparations
Since the discovery of insulin in the 1920’s there 
have been significant improvements in the formu-
lations available. Most people with type 1 diabe-
tes have transitioned from animal to human and 
then to analogue insulins; the latter are usually 
delivered as a basal–bolus regime. Analogue insu-
lins are molecularly engineered formulations that 
have been developed to improve the pharmacoki-
netics, absorption profile and duration of action 
of human insulin.36 A detailed review of the appli-
cation of the various insulin formulations in T1D 
is beyond the scope of this article so the authors 
will make the assumption that most readers will 
accept that optimal insulin replacement uses ana-
logue insulin either as part of a multi-injection 
regimen or with an insulin pump.
When used in a multi-dose regimen (MDI), it is 
established that both rapid-acting insulin ana-
logues (e.g. Rys et al.37) and first generation basal 
insulin analogues (e.g. Szypowska et  al.38) are 
associated with less hypoglycaemia, especially 
through the night. More recently, we have seen 
the development of ultra-long acting analogue 
preparations; degludec and glargine U300. In the 
BEGIN Basal–Bolus Type 1 study, nocturnal 
hypoglycaemia was 25% lower with degludec 
over glargine U100,39 while in the SWITCH 1 
trial overall rates of symptomatic hypoglycaemia, 
nocturnal symptomatic hypoglycaemia and severe 
hypoglycaemia were reduced by degludec com-
pared with glargine U100,40 although effects on 
hypoglycaemia awareness were not reported.
Thus, in the management of the individual with 
T1D who has recurrent hypoglycaemia, optimal 
insulin replacement when part of a multi-dose 
regimen, should usually involve the use of rapid 
acting insulin analogues and if available ultra-
long acting basal analogues.
Technology
There have been significant technological 
advancements in insulin delivery systems and glu-
cose monitoring devices over the last few decades 
that are having a major effect on the management 
of people with T1D and are a particularly useful 
way to manage the individual with IAH.
Insulin pump therapy
Continuous subcutaneous insulin infusion 
(CSII)41,42 via an insulin pump allows insulin to 
be delivered at varying rates throughout the day. 
This should allow more flexibility to the individ-
ual and allow dosing that more closely mimics 
normal glucose homeostasis. However, the evi-
dence that CSII reduces the frequency of severe 
hypoglycaemia compared with MDI is mixed, 
with one meta-analysis showing no difference,43 
and another a small benefit.44 In both meta- 
analyses the studies included pre-dated the ultra-
long basal insulin analogues with their improved 
pharmacodynamics, and there is little informa-
tion provided regarding the additional education 
provided to those using CSII. In the more recent 
HypoCOMPASS study, which randomised par-
ticipants to MDI or CSII, no significant differ-
ences in robust measures of the hypoglycaemic 
response and hypoglycaemia awareness were evi-
dent between treatment modalities.26,27 Similarly, 
in the Relative Effectiveness of Pumps Over MDI 
and Structured Education (REPOSE) study, 248 
people with T1D were randomised to CSII 
(n = 132) or MDI (n = 128), following completion 
of the DAFNE structured education programme 
and followed for 24 months. No statistically 
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significant differences in change from baseline in 
HbA1c or frequency of severe hypoglycaemia 
were found between groups, although both 
groups showed an improved HbA1c and reduced 
severe hypoglycaemia compared with baseline.45 
These results suggest that the CSII offers no 
additional benefit to MDI in the treatment of 
those with IAH, so the choice of therapy should 
be driven by patient preference.
CGM and Flash GM
In a meta-analysis of six randomised controlled 
trials (n = 892) real-time CGM (Rt-CGM) was 
reported to lead to an overall reduction in HbA1c 
of 0.3%, and a 23% reduction in median expo-
sure to hypoglycaemia, but no reduction in severe 
hypoglycaemia compared with SMBG.46 IN 
CONTROL was a 16-week cross-over study, 
comparing CGM with SMBG in adults with T1D 
and IAH, following a 6-week run-in period involv-
ing diabetes management re-education.47 This 
study reported significantly fewer severe hypogly-
caemic episodes with the use of CGM compared 
with SMBG, but no significant difference were 
seen in self-reported hypoglycaemia awareness 
scores.47 Similar findings have been reported for 
Flash GM (FGM), where improvements in gly-
caemic control and reductions in episodes of 
hypoglycaemia correlated to the frequency of 
scanning.48–50 One issue emerging for CGM and 
FGM is that both devices are less accurate during 
hypoglycaemia (e.g. Freckmann et al. and Farrell 
et al.51,52), and may therefore not detect all hypo-
glycaemic events. This may explain why they have 
not been shown in clinical trials to improve hypo-
glycaemia awareness. In addition, a recent obser-
vational study of people with T1D using CGM 
found that, while the overall incidence of severe 
hypoglycaemia declined, those with IAH contin-
ued to experience up to a six-fold increased risk 
for developing severe hypoglycaemia despite the 
use of CGM.53 That being said, both FGM and 
CGM remain very useful tools that aid the man-
agement of those with IAH through providing 
information about blood glucose levels, the direc-
tion and rate of change in glucose, and for CGM, 
alarms that alert the individual to impending 
hypoglycaemia.
Sensor augmented pumps
Sensor augmented pump (SAP) therapy consists of 
an integrated system of an insulin pump, providing 
a continuous subcutaneous insulin infusion (CSII), 
with a CGM and a transmitter to send glucose 
readings wirelessly to the pump. The sensors con-
tinuously measure interstitial glucose levels provid-
ing readings, trends and warnings against pre-set 
high and low parameters. This information guides 
the user to make changes to their insulin therapy in 
‘real time’. There are two types of SAP available: 
in the first, the insulin dosing software is independ-
ent of the CGM and therefore the user adjusts the 
basal rate manually when required; the second 
type is a more integrated device that allows for 
automated suspension of basal insulin delivery in 
response to a predicted or detected low glucose 
level. It is worth noting that, for all SAP devices, 
meal and correction bolus’ need to be delivered 
manually with support from an insulin pump bolus 
wizard calculator.
There have been two multicentre RCTs compar-
ing SAP treatment with MDI plus SMBG treat-
ment. The STAR 3 trial randomised 329 adults 
and 156 children with T1D and suboptimal gly-
caemic control to SAP or MDI. The SAP con-
sisted of a CSII and CGM that were integrated. 
Significant benefits in favour of SAP were seen in 
HbA1c after 6 months, but there was no differ-
ence between groups in rates of severe hypogly-
caemia after 12 months follow up.54 Similar 
findings were reported in the Eurhythmic Trial, 
where the benefit of SAP was primarily a greater 
HbA1c reduction over MDI.55 In contrast, using 
SAP and low glucose suspend (LGS) compared 
with standard CSII therapy in people with T1D 
and IAH, Ly et al.56 reported a reduction in severe 
hypoglycaemia and less time with glucose levels 
lower that 70 mg/dl (3.9 mmol/l) and 60 mg/dl 
(3.3 mmol/l) with SAP and LGS.
Closed-loop artificial pancreas
A closed-loop system or artificial pancreas is com-
posed of three components; a continuous glucose 
monitor, CSII to deliver hormones and a dosing 
algorithm to control hormone delivery. There are 
two types of artificial pancreas that have been 
developed: single-hormone systems that deliver 
insulin and dual-hormone systems that infuse 
both insulin and glucagon.
Single-hormone closed-loop systems have been 
shown to reduce time in hypoglycaemia (usually 
defined as <3.9 mmol/l in these trials) by approxi-
mately 50% compared with standard CSII.57 
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However, many of these studies have been of short 
duration, often taking place in clinical research 
facilities, and few have included subjects with 
IAH. Abitbol et al. carried out a randomised cross-
over study comparing dual and single hormonal 
artificial pancreas systems in 35 people with T1D 
(17 hypoglycaemia aware and 18 hypoglycaemia 
unaware).58 Both single and dual hormone sys-
tems were reported to reduce hypoglycaemia epi-
sodes (<3.0 mmol/l); however, there was no 
statistical significance between the two systems.
Overall, whilst there have been impressive tech-
nological advances over the past two decades in 
insulin delivery systems and glucose sensors that 
may certainly lessen the burden of hypoglycaemia 
and aid management when used appropriately, 
the technologies do still have some limitations 
that mean it is yet to be established that technolo-
gies per se can restore hypoglycaemia awareness. 
We expect to see a number of clinical trials over 
the next few years that will better inform clinical 
decision making.
Transplant intervention
For those individuals with severe disabling hypo-
glycaemia, where education and technological 
interventions have proven unhelpful, pancreas 
transplantation either as a whole pancreas or pan-
creatic islets is a therapeutic option. Patients with 
T1D who have undergone either islet or pancreas 
transplantation recover two of the primary physi-
ological defects in T1D , namely endogenous 
insulin suppression and glucagon secretion dur-
ing hypoglycaemia.59,60 Both islet and pancreas 
transplant recipients also have improved epineph-
rine and autonomic symptom responses to hypo-
glycaemia, as well as a normalised endogenous 
glucose response to insulin-induced hypoglycae-
mia, which is essential for both prevention and 
recovery from hypoglycaemia.59,60 Interestingly, 
recent work suggest that it may take up to 
18 months for the epinephrine and symptom 
responses to hypoglycaemia to normalise post-
transplant, suggesting that the prolonged expo-
sure to recurrent hypoglycaemia prior to 
transplant resulted in substantial modification of 
the glucose-sensing network.61
Novel therapies
A few experimental therapies may also emerge 
from our understanding of those mechanisms that 
lead to the development of IAH in T1D. For 
example, formoterol fumerate, an inhaled highly 
selective β2-adrenoreceptor agonist, was shown to 
increase the counter regulatory responses to hypo-
glycaemia in a small study of people with T1D.62 
While infusion with the opiate receptor blocker 
Naloxone during antecedent hypoglycaemia was 
shown to prevent experimentally induced defects 
in epinephrine release during subsequent hypogly-
caemia in people with T1D.63 In another pre-
clinical study, George et al. reported a 37% increase 
in the epinephrine response to hypoglycaemia fol-
lowing oral delivery of the ATP-sensitive potas-
sium channel opener, diazoxide, in a small cohort 
of people with T1D and IAH.64 Finally, in a 
recently published study, a single intervention 
with high intensity exercise (HIT) was shown to 
improve hypoglycaemia counter regulation and 
awareness in a study of 12 subjects with long-
standing T1D and IAH.65 This study was based 
on the hypothesis that IAH develops as a result of 
habituation to repeated hypoglycaemia, and that 
introduction of a novel strong stimulus (e.g. HIT) 
can dishabituate (restore) the habituated response. 
An on-going clinical study, HIT4HYPOs, is seek-
ing to determine if the benefits are sustained over 
4 weeks of a HIT programme.66
Conclusion and management strategies
IAH remains a concern and problem for many 
people with long duration T1D. While there are 
an increasing number of technologies in place to 
aid the management of T1D, few have been 
robustly demonstrated to restore hypoglycaemia 
awareness. Management strategies should aim to 
individualise treatment targets and therapies 
based on individual abilities and preferences, as 
well as local resources. The Clinical Practice 
Recommendation published in Diabetes Care in 
2015 for people suffering from problematic hypo-
glycaemia provides a useful framework in this 
context. In this, Choudhary and colleagues rec-
ommended health care professionals adopt a 
four-stage, tiered algorithm to individualise ther-
apy based on a composite target of optimal glu-
cose control without problematic hypoglycaemia 
(Figure 1).67 A detailed enquiry into history of 
hypoglycaemia and level of hypoglycaemia aware-
ness are central to the assessment of all people 
with insulin-treated diabetes and, for those with 
problematic hypoglycaemia, an enquiry into 
potential causes, risk factors or co-morbidities 
that may precipitate the events. A robust evidence 
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base also supports the first management step, 
which is to use a structured education programme 
or hypoglycaemia-specific education program. 
The four-stage algorithm recommends MDI with 
SMBG as part of the first line of therapy with 
CSII with SMBG or MDI, with rt-CGM as the 
preferred second stage. However, the increasingly 
widespread use of FGM and the failure of RCTs 
to show benefit of CSII over MDI, would suggest 
that stage 1 and 2 can be more usefully combined 
and the choice of intervention largely left to 
patient preference and local resources. One might 
then consider rt-CGM as the logical next step for 
the individual who still experiences problematic 
hypoglycaemia, before progressing to SAP with 
or without low glucose suspend. Finally, for the 
individual whose quality of life is severely dis-
rupted by recurrent problematic hypoglycaemia, 
pancreas or islet transplantation may be required.
While technologies will continue to evolve they 
are not without limitations and remain largely 
accessible only in wealthier countries. Therefore, 
there remains a pressing need to increase our 
understanding of the underlying mechanisms that 
lead to the development of IAH so we will be in a 
better position to consider how to manage this 
complication. For example, restoration of gluca-
gon secretion during hypoglycaemia would be a 
major breakthrough, but an appreciation and 
understanding of why this defect develops in dia-
betes is first required. If indeed IAH develops as a 
habituated process, structured education focus-
sing on strict avoidance of hypoglycaemia will be 
key, along with cognitive behavioural therapy and 
psychological interventions to support hypogly-
caemia avoidance and aid chronic changes in 
behaviour. Novel strategies such as dishabitua-
tion may also be an option to restore hypoglycae-
mia awareness. Further studies are required 
focussing on those with IAH with appropriate 
outcomes to assess restoration of hormonal and 
symptomatic awareness. In addition, an agreed 
definition of hypoglycaemia used by all investiga-
tors is imperative to allow study outcomes to be 
compared and analysed. No one insulin prepara-
tion, delivery or monitoring system is suitable for 
every person with T1D, it should to be tailored to 
the individual. As with the clinical approach to 
managing IAH, it should be patient centred and 
focussed on the individuals’ requirements, under-
standing and resources available.
Evaluate underlying causes and status against treatment targets
Advance therapy if not to target [no SH in past 3-6 months and 
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Figure 1. Four-stage, tiered algorithm to individualise therapy based on a composite target of optimal glucose 
control without problematic hypoglycaemia.
HbA1c, glycated haemoglobin; LGS, low glucose suspend; MDI, multiple daily injections; rt-CGM, real-time continuous 
glucose monitoring; SAP, sensor augmented pump; SH, severe hypoglycaemia; SMBG, self-monitoring blood glucose.
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